Determination of Beta-Defensin Genomic Copy Number in Different Populations: A Comparison of Three Methods by Fode, Peder et al.
Determination of Beta-Defensin Genomic Copy Number
in Different Populations: A Comparison of Three
Methods
Peder Fode
1., Cathrine Jespersgaard
2., Robert J. Hardwick
3, Helen Bogle
3¤, Michael Theisen
2, Daniel
Dodoo
4, Martin Lenicek
5,6, Libor Vitek
5,6, Ana Vieira
7, Joao Freitas
7, Paal Skytt Andersen
1, Edward J.
Hollox
3*
1Department for Microbiological Surveillance and Research, Statens Serum Institut, Copenhagen, Denmark, 2Department of Clinical Biochemistry and Immunology,
Statens Serum Institut, Copenhagen, Denmark, 3Department of Genetics, University of Leicester, Leicester, United Kingdom, 4Noguchi Memorial Institute for Medical
Research, University of Ghana, Legon, Ghana, 5Department of Clinical Biochemistry and Laboratory Diagnostics, 1
st Faculty of Medicine, Charles University in Prague,
Prague, Czech Republic, 64
th Department of Internal Medicine, 1
st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, 7Department of
Gastroenterology, Hospital Garcia de Orta, Almada, Portugal
Abstract
Background: There have been conflicting reports in the literature on association of gene copy number with disease,
including CCL3L1 and HIV susceptibility, and b-defensins and Crohn’s disease. Quantification of precise gene copy numbers
is important in order to define any association of gene copy number with disease. At present, real-time quantitative PCR
(QPCR) is the most commonly used method to determine gene copy number, however the Paralogue Ratio Test (PRT) is
being used in more and more laboratories.
Findings: In this study we compare a Pyrosequencing-based Paralogue Ratio Test (PPRT) for determining beta-defensin
gene copy number with two currently used methods for gene copy number determination, QPCR and triplex PRT by typing
five different cohorts (UK, Danish, Portuguese, Ghanaian and Czech) of DNA from a total of 576 healthy individuals. We
found a systematic measurement bias between DNA cohorts revealed by QPCR, but not by the PRT-based methods. Using
PRT, copy number ranged from 2 to 9 copies, with a modal copy number of 4 in all populations.
Conclusions: QPCR is very sensitive to quality of the template DNA, generating systematic biases that could produce false-
positive or negative disease associations. Both triplex PRT and PPRT do not show this systematic bias, and type copy
number within the correct range, although triplex PRT appears to be a more precise and accurate method to type beta-
defensin copy number.
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Introduction
Characterization of genetic variants is fundamental in under-
standing human heterogeneity and susceptibility to disease.
Regions where humans differ in diploid DNA dosage are known
as copy number variations (CNV) and are an important
component of genetic variation. CNVs are believed to encompass
more nucleotide content than single nucleotide polymorphisms
(SNPs) [1] and between 12% and 18% [2,3] of the euchromatic
human genome is suggested to be copy number variable [4]. The
use of array-comparative genomic hybridisation (array-CGH) and
next-generation sequencing techniques will probably reveal an
even greater proportion of structural variation among individuals
and populations [5,6]. CNVs can alone or in combination with
SNPs correlate with certain diseases, or are associated with
increased susceptibility to diseases [7–9] including psoriasis [10–
12], autism [13], cancer [14], schizophrenia [15–17], systemic
lupus erythematosus [18–20], Alzheimer’s disease [21], Charcot-
Marie-Tooth disease [22,23], Parkinson’s disease [24] and
autoimmunity [25].
One region showing extensive CNV is found in the 8p23.1
chromosome [26–28]. The region contains a cluster of defensin
genes including the DEFB4 and the DEFB103 which encode
human b-defensins 2 and 3 (hBD2, hBD3), respectively. Defensin
genes encode small cationic peptides that have antimicrobial
activity and have multi-functional activity: they function as chemo-
PLoS ONE | www.plosone.org 1 February 2011 | Volume 6 | Issue 2 | e16768attractants for T-lymphocytes, monocytes and dendritic cells
[29–32]. b-defensins induce the production of diverse chemokines
and cytokines such as MCP-1, macrophage inflammatory protein
3-a (MIP-3), RANTES, IL-6, IL-10, interferon-inducible protein
10, TNF-a and IL-1b, mainly in keratinocytes [33,34]. hBD3
mediates monocyte/macrophage migration [35], can signal
through melanocortin receptor 1 [36], and may function as an
anti-inflammatory molecule [37].
The beta-defensin cluster varies in copy number between 2 and
12 copies per diploid genome with most people having 2–7 copies
[28,38–41]. Because, to date, all evidence suggests this defensin
cluster varies in copy number en bloc, an assay for any point within
the defensin cluster can be assumed to measure copy number
across the whole region [42]. Though attention has moved from
CNV discovery in small cohorts to CNV typing in larger cohorts,
it is still a major challenge to determine exact copy numbers.
Although several studies have been performed to characterize
CNVs, comparing results from these studies has been hindered by
small sample sizes and different study designs and analytical
methods resulting in conflicting results [43,44] illustrating the need
for an accurate method and controls for future work. In particular,
the use of real-time QPCR methods, which appear attractive due
Figure 1. Illustration of the PPRT assay. A. Primer design and sequence of region test and reference regions. The sequence shows several
differences between chromosome 8 (test) and chromosome 21 (reference). The red arrow show the variable position used to distinguish test from
reference amplicon sequences, and quantified by PPRT. F: forward primer, R: reverse primer, and S: sequencing primer. B. Pyrograms from PPRT
testing of samples with 3 and 4 beta-defensin copies. Two variable sites are highlighted in yellow. The second variable site (corresponding to the site
highlighted with the red arrow in Figure 1a), with the percentage of each allele shown, gave reproducible values and used for quantification. For the
top pyrogram, the ratio of the C variant (representing the test amplicon) to the T variant (representing the reference amplicon) is 1.5:1, indicating a
diploid copy number of three for the test sequence. For the bottom pyrogram, the ratio is 2:1, indicating a diploid copy number of four.
doi:10.1371/journal.pone.0016768.g001
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simplicity, has come under some scrutiny [45], with the suggestion
that batch variation can generate false positive associations of copy
number and disease [46,47]. Since CNVs may play a role in
susceptibility to certain diseases, due to variation in gene
expression [48,49], it is of great importance to find approaches
to determine exact copy numbers.
PRT addresses one of the major drawbacks of QPCR, namely
the problem of bias due to different amplification kinetics of test
and reference amplicons [50]. By careful design of primers to a
repeat region within the CNV, it is possible to amplify two almost
identical regions using just one set of primer pair, the test amplicon
within the CNV, and the reference amplicon outside the CNV,
ideally on another chromosome. A small difference in length
between the amplified products distinguishes test amplicon from
reference amplicon. Using PCR and subsequent fragment analysis
by capillary electrophoresis it is possible to determine the copy
number. Here, we evaluate a simple, cost-effective, high-
throughput adaptation of the PRT method to determine gene
copy number using the pyrosequencing technique to quantify
sequence differences between the test and reference PRT
amplicons [42,51,52], and compare this pyrosequencing PRT
(PPRT) with the published triplex PRT [53] method and real-time
QPCR. We determined the gene copy numbers for 576 healthy
individuals from five different populations using these three
methods, compared the copy number distributions generated by
the different methods, and compared the copy number distribu-
tions across the different populations.
Materials and Methods
Study population
Unrelated DNA samples from normal healthy individuals from
five different demographic population groups, Denmark (n=174),
Czech Republic (n=21), Ghana (n=100), Portugal (n=91), and
the United Kingdom (the European Collection of Cell Cultures
ECACC (Cat. No.: HRC-1 and HRC-2); (n=190) were used in
the study.
Ethics statement
All samples were gathered with full ethical consent and
appropriate documentation as stipulated by the ethical consent,
which normally involved written informed consent. For Portu-
guese samples, the local ethics committee of Hospital Garcia de
Orta, Almada, Portugal, gave its approval for a genetic study using
blood samples from local patients and normal volunteers. For
Czech samples, the study has been approved by the Ethical
commitee of the General Faculty Hospital in Prague. For
Ghanaian samples, approval of the Institutional Review Board
of Noguchi Memorial Institute for Medical Research, University
of Ghana was given. For Danish samples, they are a standard set
of anonymised DNA samples provided for standardisation
purposes and quality assurance, and were not required under
Danish law to pass the Danish Ethics Approval system. Other
samples were from immortalised lymphoblastoid cell lines, which
had been derived from B-cell lymphocytes with full ethical consent
by the suppliers (ECACC and Coriell Cell Repositories).
DNA extraction
Genomic DNA was isolated from samples of venous blood, anti-
coagulated with EDTA and purified using the QIAamp DNA
Blood Mini Kit (Qiagen, Hilden, Germany) according to the
manufacturer’s protocol and eluted in water. The UK samples
were purified using an in-house magnetic bead affinity method
Table 1. Copy number estimates using different methods on a panel of DNA samples.
Sample
PRT
(reference 50)
PPRT
(this paper)
PPRT
(reference 42)
Triplex PRT
(this paper)
MLPA
(reference 42)
Q-PCR
(this paper)
C0088 4 4 3 4 4 4
C0096 5 5 3 5 5 4
C0187 4 4 4 4 4 3
C0195 4 4 4 4 4 4
C0748 4 3 4 4 4 4
C0766 3 2 2 3 3 3
C0863 5 5 4 5 5 5
C0877 3 3 3 3 3 3
C0888 5 5 4 5 5 5
C0909 5 4 4 5 5 6
C0913 3 3 3 3 3 3
C0917 4 4 3 4 4 4
C0937 4 4 4 4 4 4
C0960 3 3 2 3 3 3
This table summarises published data and data from this paper where a panel of DNA samples from the UK population have been typed for beta-defensin copy number
by different laboratories using different methods.
doi:10.1371/journal.pone.0016768.t001
Table 2. Percentage of discordant results between the three
different methods.
PPRT Triplex PRT QPCR
PPRT - - -
Triplex PRT 47.3% - -
QPCR 67.7% 60.2% -
Pairwise discordance rates are shown, for a first-pass test of all 576 samples.
doi:10.1371/journal.pone.0016768.t002
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PLoS ONE | www.plosone.org 3 February 2011 | Volume 6 | Issue 2 | e16768Figure 2. Histograms of raw unrounded copy number estimates. The raw unrounded copy number estimates for all 576 samples analysed. Unrounded
copy number estimates are in bins of 0.1, with the count of each bin displayed on the y-axis: a) from QPCR assay, b) from PPRT assay, and c) from triplex PRT assay.
doi:10.1371/journal.pone.0016768.g002
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Czech DNA samples were extracted using a routine ‘‘salting out’’
and ethanol precipitation procedure.
Quantitative real-time PCR for copy number
determination
A duplex TaqMan real-time quantitative PCR-based assay was
developed for the detection of beta-defensin genomic copy number
using RNaseP as reference gene. Primers and probes for
amplification of a region near the DEFB103 gene were designed
using the Primer Express software, version 2.0 (Applied Biosys-
tems, Foster City, CA). The sequences of the primers and probes
were as follows: DEFB103 forward primer (59 CAT AGG GAG
CTC TGC CTT ACC A 39); DEFB103 reverse primer (59TGC
AGA ACA CAC CCA CTC ACT C 39) and DEFB103 probe (59
FAM - TGG GTT CCT AAT TAA C – MGB 39). The sequence
for RNaseP is not known since it is a commercial available kit
(VIC labelled, Cat. no. 4316844, Applied Biosystems). The
amplification efficiencies of the target genes and the reference
genes were tested to be approximately equal not varying more
than 5% from each other. Optimizing runs were performed to
define limiting primer concentrations for the duplex assay. The
PCR reactions (20 ml) were carried out in triplicate with 10–75 ng
of template DNA, 1 x Brilliant II QPCR master mix (Stratagene,
La Jolla, CA), 400 nM of DEFB103 probe, 600 nM DEFB103
primers and 1 x RNaseP primer mix. Each plate included
triplicate wells of ‘‘no template control’’ and 4 control samples.
QPCR was performed using a Stratagene MX3000P machine
(Stratagene) using the following conditions 95uC for 10 min
followed by 40 cycles of 95uC for 15 sec, and 60uC for 1 min. In
all runs samples from Coriell Institute for Medical Research
(Camden, NJ) with known copy number were included[50]: 3
copies per genome (Coriell cat no.: NA10861), 4 copies per
genome (Coriell cat no.: NA07048), 5 copies per genome (Coriell
cat no.: NA10846), and 7 copies per genome (Coriell cat no.:
NA10847). These were used to generate a correction curve by
linear regression, and corrected copy number estimates calculated
for each sample calculated using this run-specific regression
equation.
Paralogue Ratio Test for copy number determination
PRT was performed as described previously [53]. Briefly, the
assay used comprises two PRT assays and a multiallelic ratio test
[52] to gain three independent measurements of beta-defensin
repeat copy number. This test, performed in duplicate, produces
six estimates of beta-defensin copy number in a single fluorescent
capillary run, and each test is independently normalised against six
samples of known copy number to control for variation between
experimental runs. The six values are combined using a
maximum-likelihood method [53,54] to give the best estimate of
the integer copy number for each sample, together with an
associated significance value reflecting the confidence we have in
that typed copy number compared to all other copy numbers
between 1 and 10. For analyses involving raw non-integer copy
number estimates, we calculated means of the six copy number
estimates, each estimate weighted according to the inherent
variability of each individual assay.
Figure 3. Bland-Altman plots showing differences in copy
number estimation between methods. a) Triplex PRT minus QPCR,
b) Triplex PRT minus PPRT, c) Triplex PRT minus QPCR, good quality
DNA only.
doi:10.1371/journal.pone.0016768.g003
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number determination
PRT was carried out essentially as described previously [50]. The
beta-defensin cluster region on chromosome 8 and an identified
paralogue gene (HSPD21 on chromosome 21) 3 kb distal to the
DEFB4 gene with only two copies per genome were PCR amplified.
The resulting PCR amplicons differed at 10 positions with an 8 bp
(BLAST) difference in length. One of the positions where the
ampliconsdifferedwas used to quantifythetwo chromosomeregions
against each other by pyrosequencing across it. Primers for the
pyrosequencing assay were designed using the PSQ assay design
software version 1.0.6 (Qiagen, Hilden, Germany). The following
sequence was analysed with the position that varied between
chromosome 8 and 21 marked with red: KATGCYAT (Figure 1).
For the PCR, 20 ng of genomic DNA in a total volume of 50 ml
using a forward primer (59-GAGGTCACTGTGATCAAAGAT-39)
and a reverse primer (59-Biotin- AACCTTCAGCACAGC-
TACTC-39) was used was used together with Q-solution (Qiagen),
10 mM dNTP and Tempase polymerase. PCR was performed on a
thermocycler using the following conditions: 15 min at 95uC
followed by 35 cycles of 95uC for 30 s, 53uC for 30 s and 72uC
for 45 s and one extension step at 72uC for 10 min. The biotin-
labeled PCR products were immobilized on streptavidin Sepharose
(GE Healthcare, Uppsala, Sweden) by mixing 40 ml of the PCR
product with 3 ml streptavidin Sepharose suspension, 40 mlw a t e r ,
and 37 ml 1 x binding buffer (Qiagen). The suspension was shaken at
room temperature for 10 minutes. To remove unbiotinylated DNA
the samples were sequentially washed in 70% ethanol for 5 seconds,
denaturated in 0.5 M NaOH for 5 seconds and additional washing
in 1x washing buffer (Qiagen) for 5 seconds. This was done using the
PyroMark Vacuum Prep Tool (Qiagen). After the last wash the
ssDNA biotinylated DNA was transferred to 39 ml1xa n n e a l i n g
buffer (Qiagen) and 1 ml sequencing primer (59-AGGTCACTGT-
GATCAAAGAT-39). The suspension was heated to 80uCf o r2
minutes and was equilibrated to room temperature for 5 minutes in
order to let the sequencing primer anneal. The sequencing reaction
was performed using the Pyro Gold Reagent Kit (Qiagen) in the
PSQ 96 MA Pyrosequencer (Qiagen) according to the manufactur-
er’s instructions. The relative percentages of the two variants were
calculated by the accompanying software and were used for the gene
copy number determination. Positive controls with known copy
number in each run were used to generate a correction curve by
linear regression, and corrected copy number estimates calculated
for each sample calculated using this run-specific regression
equation. A ‘‘no template control’’ was included in each run.
Statistical analysis
Statistical analysis was performed using GraphPad InStat 3
(GraphPad Software, La Jolla, USA) and Microsoft Excel.
Results and Discussion
We have developed a version of the PRT method that uses
pyrosequencing and quantification of different sequence variants
to distinguish test and reference amplicons (pyrosequencing PRT,
PPRT). A pyrosequencing approach to determining beta-defensin
copy number has been described previously [42], using different
primers and an alternative paralogue on chromosome 5, giving
results that differed considerably from MLPA and previously
published estimates of the same samples [50]. Nevertheless, given
the potential of PPRT to automated copy number typing, and the
previously published examples of pyrosequencing to quantify
alleles, a reliable PPRT method would be a very useful tool to
investigate the role of beta-defensin copy number and disease. We
designed an assay that would allow PCR amplification across a
‘‘test’’ region distal to DEFB4 co-amplifies a ‘‘reference’’ region on
chromosome 21. Pyrosequencing of the product allows quantifi-
cation of a particular sequence variant that reports copy number
by distinguishing test from reference amplicons.
We determined beta-defensin gene copy number using PPRT
and two other independent methods on DNA samples from 576
individuals from five populations. Comparison of copy number
estimates for 14 samples measured using several different methods
shows that triplex PRT and MLPA give exactly the same copy
numbers as the previously published PRT method (Table 1).
PPRT performs better than a previous pyrosequencing-based
assay, but showed three discrepancies with PRT/triplex PRT/
MLPA. Extending this analysis, we examined the proportion
discordant copy number calls between the three methods (Table 2).
There is a very high frequency of discordant calls, although PPRT
and triplex PRT are the least discordant (47.3%). Such variation
in copy number calling between methods is problematic and is
likely to reflect error in the methods used. We decided to
investigate the sources of error by examining the raw data in more
detail. The raw unrounded data are shown as histograms in
Figure 2. If our underlying biological assumption is that copy
number varies discretely as complete integers (2, 3, 4 etc) then we
would expect our data to reflect that underlying biological reality
by clustering of unrounded data about those integer values. Both
QPCR and PPRT show no evidence of clustering (Figure 2a, 2b),
compared to triplex PRT (Figure 2c), which shows evidence of
clustering, revealed by peaks in the histogram corresponding to
integer copy numbers. This is due, at least in part, to repeat
testing, because each triplex PRT copy number estimate is from
duplicate testing of three different assays, compared to triplicate
testing of one assay for the QPCR, and one test for the PPRT.
Indeed, on repeat testing of a selection of UK samples, the
coefficient of variation of PPRT is 0.05 compared to 0.08 for
triplex PRT, suggesting that PPRT is as precise as triplex PRT,
although PPRT assays a single locus, while the triplex PRT assays
three different loci within the beta-defensin CNV.
Both PPRT and triplex PRT give a copy number distribution of
between 2 and 6 copies, with a few samples showing a higher copy
number. However, the QPCR assay gives a considerably broader
distribution, with more samples showing apparently higher copy
number, and a significant number of samples showing copy
number higher than 10. This is reflected in the Bland-Altman plots
comparing the raw copy number estimates between the different
methods (Figure 3), and the observation that QPCR can
overestimate copy number values agrees with other reported
studies [55].
We took the raw copy number data and divided, according to
cohort, by separating the Ghanaian and Portuguese cohorts from
the UK, Danish and Czech cohorts. Plotting this raw data as a
histogram shows that DNA cohort origin is clearly responsible for
systematic copy number calling bias in QPCR between ‘‘poor
Figure 4. Histograms of raw unrounded copy number estimates comparing results from poor and good quality DNA. The raw
unrounded copy number estimates for all 576 samples analysed. Unrounded copy number estimates are in bins of 0.1, with the count of each bin
displayed on the y-axis. Results from the good quality DNA cohorts (UK, Danish, Czech) are shown in grey, results from the poor quality DNA cohorts
(Portuguese, Ghanaian) are shown in black. a) From QPCR assay, b) from PPRT assay, c) from triplex PRT assay.
doi:10.1371/journal.pone.0016768.g004
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‘‘good quality’’ DNA from the UK, Danish and Czech cohorts
(Figure 4a) but had no effect on copy number calling for the two
PRT-based methods (Figure 4b and 4c) but. For the UK, Danish
and Czech cohorts, QPCR gives a copy number distribution in a
range comparable with the PRT-based methods, while for the
Ghanaian and Portuguese cohorts QPCR systematically overes-
timates copy number, often by several copies. Because each cohort
was analysed as a batch, it is possible that biases in the
normalisation to known copy number controls included on every
PCR plate (see Methods) could generate this effect. We compared
the results from the known copy number controls across each
cohort-specific plate for all three methods, and found no evidence
of systematic differences (Figure 5).
We therefore reasoned that systematic difference in DNA
quality between the DNA sample cohorts may be responsible for
this effect. Cukier and colleagues recently showed that degraded
DNA could give spurious CNV findings despite the presence of
multiplexed internal samples in QPCR assays [45]. Although these
five cohorts are from different biological sources, DNA extracted
using different methods, and have different histories of transport
and storage associated with them, they do not appear to vary with
DNA ‘‘quality’’ (Table 3). We investigated whether the systematic
bias in QPCR results was due to DNA degradation by analysing
selected samples by agarose gel electrophoresis or whether it was
due to salt contamination by examining absorbance at 230 nm.
Neither measure correlated with the ‘‘quality’’ of the DNA in
giving appropriate QPCR results, so we do not yet understand the
physical basis for the different DNA qualities of these cohorts.
This raises questions about the applicability of QPCR in
measuring DNA copy number, particularly as we cannot, as yet,
identify the factor that is responsible for this effect, ruling out a
priori determination of the applicability of each sample for copy
number calling by QPCR. Furthermore, it is unclear whether
internal controls constructs would remove this effect, given that it
is a property of the genomic DNA itself rather than any effect of
aberrant normalisation.
Taking the triplex PRT data as representing the correct copy
number of the samples typed, we investigated whether there was
any significant difference between copy number distributions in
the five different populations. There was no significant difference
between the means (one-way ANOVA, p.0.05), reflecting
essentially no difference between populations within Europe or
between European and Ghanaian populations (Table 4). This is
consistent with previous studies [39]. This probably reflects the
high mutation rate at this locus, causing any population specific
signatures to be rapidly erased. This also means that real case-
control differences from robust studies are less likely to be
confounded by cryptic population stratification than similar SNP
studies, although we would recommend that population stratifi-
cation is controlled for as far as possible.
Differences in beta-defensin copy number may have important
clinical consequences in the susceptibility to, and progression of, a
variety of diseases with an inflammatory or infectious etiology.
Figure 5. Scatterplots showing reproducibility of positive
controls between different experiments. These figures plot known
copy number from control samples against actual raw copy number
values, for each experiment. Note that all five populations are not
represented: several experiments tested samples from more than one
population, which was an additional control against systematic bias.
The legend on the graphs indicates the population from which the
majority of samples in that particular experiment derived. a) QPCR
assay, b) PPRT assay, c) Triplex PRT assay.
doi:10.1371/journal.pone.0016768.g005
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essential when investigating subtle changes in copy number
distribution between patients and healthy controls, which may
reflect an effect of beta-defensin copy number on susceptibility to
the disease under study. In summary, we show that PPRT is a
practical high-throughput approach, although we would recom-
mend multiplicate PPRTs per sample are required for sufficient
accuracy for case-control analyses, and careful quality-control
performed for every experiment. PPRT is cost-effective, with a
single test priced around J0.75, compared with around J1.2 for a
triplex PRT. We hope that with an increasing focus on reliable
methods to type beta-defensin copy number variation we will be in
a position to investigate the role of this complex locus in disease.
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2 21 4 2 33 2 200
3 26 14 32 19 19 19 11 12 1 5
4 88 46 68 40 49 49 41 45 8 38
5 53 28 43 25 21 21 28 31 7 33
6 1 6 8 1 71 0 55 7 841 9
7 32 4 2 11 1 115
8 11 2 1 11 1 100
9 11 0 0 11 0 000
Beta-defensin copy number, as determined by triplex PRT, are shown for the five populations studied, as counts and as a percentage.
doi:10.1371/journal.pone.0016768.t004
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